QUOTE AND NEWS
FierceBiotech  Jul 19  Comment 
Eli Lilly likes what it sees in Adimab's antibody R&D platform, opting to roll it out at sites in San Diego and New York to help its antibody discovery and optimization activities.
FiercePharma  Jul 13  Comment 
Under a new patent settlement with multiple generics makers, Eli Lilly’s storied erectile dysfunction med Cialis will keep exclusive protections a little while longer.
Benzinga  Jul 13  Comment 
Jefferies raised Eli Lilly and Co (NYSE: LLY) price target from $93 to $95. Eli Lilly shares closed at $83.50 on Wednesday. Stifel boosted the price target for Hasbro, Inc. (NASDAQ: HAS) from $100 to $107. Hasbro shares closed at $112.97...
FierceBiotech  Jul 13  Comment 
Alder Biopharmaceuticals has priced a $150 million follow-on offering. The stock sale will set Alder up to forge ahead with development of a migraine drug it thinks can carve out a space in a market fought over by larger rivals such as Amgen and...
Benzinga  Jul 13  Comment 
On CNBC's "Fast Money Final Trade", Pete Najarian said airline stocks are going higher. He wants to buy United Continental Holdings Inc (NYSE: UAL). Tim Seymour recommended a long position in Delta Air Lines, Inc. (NYSE: DAL). Dan Nathan...
MarketWatch  Jul 12  Comment 
Eli Lilly & Co. said on Wednesday that as part of a settlement with generic companies over its Cialis patent, the exclusive patent is now expected to end on September 27, 2018 at the earliest, roughly a year-and-a-half earlier than the patent was...
FiercePharma  Jul 10  Comment 
Is it the end of a controversial era? Erectile dysfunction ads will no longer be seen during televised NFL football games, according to a new report.
FiercePharma  Jul 8  Comment 
If the first 6 months of pharma TV ad spending serve as any indication, 2017 could be another record-setting advertising year for the industry. Year-to-date spending on national TV pharma ads topped $1.75 billion, outpacing 2016’s half-year mark...




Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki